{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:25:26Z","timestamp":1763400326306,"version":"3.45.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jceh.2025.103173","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:33:28Z","timestamp":1755930808000},"page":"103173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Placebo Effect on Changes in Magnetic Resonance-based Endpoints in Patients With MASH: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3695-9701","authenticated-orcid":false,"given":"Matheus","family":"Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2129-4891","authenticated-orcid":false,"given":"Lubna","family":"Al-Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7205-9405","authenticated-orcid":false,"given":"Samira M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0803-7762","authenticated-orcid":false,"given":"Ivanna","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2025.103173_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jceh.2025.103173_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2025.103173_bib6","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2025.103173_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2025.103173_bib8","first-page":"6","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jceh.2025.103173_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s12072-024-10716-z","article-title":"Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals","volume":"18","author":"Souza","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2025.103173_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.103173_bib11","doi-asserted-by":"crossref","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, et al. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatol Baltim Md. Published online February 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001254.","DOI":"10.1097\/HEP.0000000000001254"},{"key":"10.1016\/j.jceh.2025.103173_bib12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.103173_bib13","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","article-title":"The placebo response in randomized trials in nonalcoholic steatohepatitis simply explained","volume":"20","author":"Rowe","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2025.103173_bib15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2025.103173_bib16","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib18","doi-asserted-by":"crossref","unstructured":"Koh B, Xiao J, Ng CH, et al. Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis. Hepatol Baltim Md. Published online July 19, 2024. doi:10.1097\/HEP.0000000000001028.","DOI":"10.1097\/HEP.0000000000001028"},{"key":"10.1016\/j.jceh.2025.103173_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.31624","article-title":"MRI-Proton density fat fraction treatment response criteria in nonalcoholic steatohepatitis","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.103173_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2008.07.013","article-title":"Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials","volume":"6","author":"Loomba","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib22","doi-asserted-by":"crossref","first-page":"102487","DOI":"10.1016\/j.jceh.2024.102487","article-title":"Response and adverse event rates with placebo in compensated MASH-related cirrhosis: a meta-analysis","volume":"15","author":"Amaral","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib23","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2025.103173_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70029","article-title":"Representation of sex, race and ethnicity in MASH randomised controlled trials: a systematic review and meta-analysis","volume":"45","author":"Souza","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2025.103173_bib25","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003520","article-title":"Enrollment in metabolic dysfunction-associated steatohepatitis clinical trials: a pooled analysis of screen failure rates","author":"Souza","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2025.103173_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jceh.2025.103173_bib27","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2025.103173_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.jceh.2025.103173_bib29","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jceh.2025.103173_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic Fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.103173_bib31","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2025.103173_bib32","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jceh.2025.103173_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.103173_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, Double-Blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.103173_bib35","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2025.103173_bib36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2025.103173_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jceh.2025.103173_bib38","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2025.103173_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib41","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2025.103173_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2025.103173_bib44","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib45","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","author":"Loomba","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.103173_bib47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.103173_bib49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib50","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220743","article-title":"MRI quantification of placebo effect in nonalcoholic steatohepatitis clinical trials","volume":"306","author":"Nedrud","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.jceh.2025.103173_bib51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cgh.2018.08.055","article-title":"Refining sample-size estimations based upon placebo response in trials of agents for nonalcoholic fatty liver disease","volume":"17","author":"Ajmera","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/apt.18498","article-title":"Meta-analysis of placebo-treated patients: dropout rates from treatment in MASH randomised controlled trials","volume":"61","author":"Souza","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2025.103173_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2025.103173_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102495","article-title":"Global epidemiology and implications of PNPLA3 I148M variant in metabolic dysfunction\u2013associated steatotic liver disease: a systematic review and meta-analysis","volume":"15","author":"Souza","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2025.103173_bib55","doi-asserted-by":"crossref","unstructured":"Abu-Rumaileh M, Dhoop S, Pace J, et al. Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis. Am J Gastroenterol. Published online March 2025. doi:10.14309\/ajg.0000000000003421.","DOI":"10.14309\/ajg.0000000000003421"},{"key":"10.1016\/j.jceh.2025.103173_bib56","first-page":"165","article-title":"Association between higher consumption of ultra-processed foods and risk of diabetes and its complications: a systematic review & updated meta-analysis","author":"Souza","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2025.103173_bib57","article-title":"The role of exercise in steatotic liver diseases: an updated perspective","volume":"45","author":"Alabdul","year":"2025","journal-title":"Liver Int"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325006735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325006735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:12:57Z","timestamp":1763399577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688325006735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0973688325006735"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2025.103173","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Effect on Changes in Magnetic Resonance-based Endpoints in Patients With MASH: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2025.103173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103173"}}